Corporate Profile｜YL Biologics Ltd.

Corporate Profile

Corporate Name:	YL Biologics Limited
Corporate Headquarters:	12F, Hamacho Center Building2-31-1, Nihonbashi Hamacho, Chuo-ku, Tokyo 103-0007
Capital:	50 million yen
Business:	Biosimilar development

Access

Access (Traffic Guidance):
Hamacho Station,Toei Subway Shinjuku Line (1 min by walk)
Ningyocho Station, Toei Subway Shinjuku Line (7 min by walk)
Ningyocho Station, Tokyo Metro Hibiya Line (7 min by walk)
Suitengumae Station, Tokyo Metro Hanzomon Line (10 min by walk)

Board of directors

Toshihiko Hibino Representative director, President	He has extensive experience in research, clinical development and marketing across multiple therapeutic areas including cardiovascular medicine. He has served as Managing Director of Corporate Planning (Vice President) of Sumitomo Dainippon Pharma Co., Ltd., Chief Cooperate Officer (COO) of JCR Pharma Co. Ltd, Senior Executive Vice President of Teva Pharma Japan Inc. and Senior Executive Vice President of Fujifilm Pharma Co. Ltd. He joined YL Biologics in December 2013 as Director at incorporation of the company and soon he assumed the role of President and Representative Director from June 2015. He also serves as External Director of Mutual Corporation.
Dr. Fabrice Egros, Representative director	Fabrice Egros is currently the President of APAC and Japan for Lupin and Vice-Chairman of the board at Kyowa. Pharm.D and Ph.D in Pharmaceutical sciences with a MBA , Fabrice Egros held various positions in the USA and in Japan as Sales and Marketing , Country management, and head of corporate development at companies like Sanofi and UCB. Prior to this Fabrice was managing global clinical development within Parke Davis , now Pfizer. Fabrice has more than 25 years of experience in the pharmaceutical industry , from Sciences to Business , with NCE , generics , Biologics and medical devices. He is also currently independent director at Syndax , a Immuno Ocolongy R&D company based in Boston , MA , USA.
Kenzo Shimomura, Director	He joined Yoshindo in 1971. Soon after his joining, he assumed the post of Board of Director. Since 1983 he has been serving as President and Representative Director for Yoshindo. He is the founder of YL Biologics and served as the founding President and Representative Director of the company upon its establishment in 2013. He currently serves as Director of YL Biologics.
Dr. Cyrus Karkaria, Director	Cyrus Karkaria is currently President of the Biotechnology division of Lupin Pharma based in Pune. Prior to that, he was Vice President at Celldex Therapeutics and CuraGen Corporation in New Haven, Connecticut, USA heading Operations and Biopharmaceutical Process Sciences. He has also held positions at Biogen Idec and Scios. He has been part of teams that have developed blockbusters in the field of neurology, immunology and oncology such as Avonex, Amevive and Tysabri (Biogen Idec). He has also developed commercial processes from the bench to manufacturing scale (2,000L to 15,000L). As part of the commercialization process he has also faced Regulatory bodies from the US FDA, EMEA, Australian TGA etc., through pre-IND to BLA filings. He holds a Ph.D. in Biochemistry from the University of Maryland and was a post-doctoral researcher at the Harvard Medical School.
Hiroki Kitamura, Director	He joined Yoshindo in 1985. He has built up abundant experiences in the areas of quality control, plant management and quality assurance. He was appointed to Director in 2013 and has been serving as Executive Vice President since 2015. He currently serves as Director of YL Biologics as well.
Dr. Sofia Mumtaz, Director	Dr. Sofia Mumtaz is currently the President-Portfolio and Legal at Lupin. Dr. Mumtaz started her career in academics and transitioned to the industry as a product development scientist. Subsequently, she transitioned to managing IP and is currently responsible for the identification and delivery of the generic product pipeline, with the legal and Global IP functions reporting into her. She is skilled in leading teams in Global portfolio strategy and R&D management, Regulatory, Intellectual property, Legal, Compliance, Government Affairs and other aspects of the generic business. In addition to managing these operational functions, Dr. Mumtaz is also responsible for setting up the branded business in Canada. She holds a PhD in Biochemistry from Delhi University and MBA from ISB.
Osamu Nakashima Statutory auditor Ashutosh Agarkar Statutory auditor